Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Under the terms of the agreement, Arrakis will lead research activities for the identification of RNA-targeted small molecule (rSM) binders against a broad set of targets nominated by Amgen
The company’s platform technology works like a compression algorithm for molecular testing and has applications in healthcare, pharmaceuticals, agriculture, animal husbandry, food safety, synthetic biology, and molecular biology research
Acquisition adds Adaptate’s novel antibody-based ?? T-cell engager platform to Takeda’s Immuno-oncology portfolio built around the Innate Immune System
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
Carisma to receive US $ 45 million up-front cash payment and investment by Moderna in the form of a US $ 35 million convertible note
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
The company is now ready to offer clinical testing anywhere in the world after early case studies conducted in Israel have demonstrated recovery within 48 hours
Syngene will also build and operate a new dedicated drug development laboratory to accelerate the advancement of Amgen R&D projects
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
